Sunday 18 October 2026
Export AGMB’s income statement to Excel — free account
AgomAb Therapeutics NV
AGMB
Insiders bought in the last twelve months.
8.28
0.05
−0.60%
Follow AGMB
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
19.05 | 6.52 |
Net Debt/EBITDA |
3.57 | 1.96 |
Debt/Assets |
0.62% | 0.65% |
Debt/Equity |
0.01 | 0.01 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.81 | 0.67 |
Capex/Depreciation |
(2.17) | (0.02) |
Interest Coverage |
(134.52) | (445.61) |
| 0.00% | (49.87%) | |
| 0.00% | (44.15%) | |
ROIC |
(167.73%) | (240.67%) |
Return on Tangible Assets |
(34.99%) | (75.13%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.14 | 0.19 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(2.06) | (108.19) |
Cash per Share |
7.42 | 243.62 |
Shareholders Equity per Share |
8.14 | 273.71 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
8.14 | 273.71 |
Free Cash Flow |
(51.40) | (58.54) |
Working Capital |
178.24 | 116.14 |
Capital Expenditures |
(0.73) | 0.00 |
Net Current Asset Value |
168.34 | 111.37 |
| Other line items | ||
Quick Ratio |
18.79 | 6.27 |
Depreciation/Fixed assets |
0.50 | 0.44 |
Cash ROIC |
(13.17%) | (20.83%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(2.03) | (108.19) |
Capex per Share |
(0.03) | (0.01) |
Average Payables |
— | 10.16 |
Average Assets |
— | 198.60 |
Average Common Equity |
— | 175.81 |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates